早期试验显示GT801,一种新的CAR-T疗法,在两个未接受化疗的患者中安全减少淋巴瘤。 Early trial shows GT801, a new CAR-T therapy, safely reduced lymphoma in two patients without chemotherapy.

Vivacta Bio报告说,在2025年的ASH会议上,人类首次对GT801(CA-T静脉治疗)进行试验,取得了早期积极成果。 Vivacta Bio reported early positive results from the first human trial of GT801, an in vivo CAR-T therapy, at the 2025 ASH meeting. 两名复发性或易碎性非Hodgkin淋巴瘤患者在四周内表现出深度B细胞耗竭和部分反应,无需化疗。 Two patients with relapsed or refractory non-Hodgkin’s lymphoma showed deep B-cell depletion and partial responses within four weeks, without needing chemotherapy. GT801,通过有针对性的脂质纳米粒子交付,安全诱导的持久CAR-T细胞扩张,高选择性且无非目标效应。 GT801, delivered via targeted lipid nanoparticles, safely induced durable CAR-T cell expansion with high selectivity and no off-target effects. 治疗是精心设计的,允许重复施用剂量,避免了传统制造。 The therapy was well-tolerated, allowed repeat dosing, and avoided traditional manufacturing. 结果证明GT801有可能简化CAR-T治疗。 The results support GT801’s potential to simplify CAR-T treatment.